Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 2 | Y006393 | — |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | 2 | Y005465 | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 2 | Y009341 | OT |
No additional AE reported; improperly stored temperature excursion; This spontaneous report was received from a nurse and referred to a patient of unknown age and gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 18-FEB-2025, the vaccines of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), and Pneumococcal 15-valent Conjugate Vaccine (VAXNEUVANCE) experienced improperly stored temperature excursion, with temperature of 32.0 Fahrenheit (F) and time frame of 2 hours 12 minutes. There was no previous temperature excursion. On 03-MAR-2025, the patient was vaccinated with these vaccines of Pneumococcal 15-valent Conjugate Vaccine (VAXNEUVANCE) injection strength 0.5ml (2nd dose, lot #Y005465, expiration date: 08-JAN-2027; dose and route were not reported); Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB) (2nd dose, lot #Y006393, expiration date: 07-NOV-2026; strength, dose, and route were not reported); Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) (2nd dose, lot #Y009341, expiration date: 24-NOV-2025, via orally; strength and dose were not reported), all for prophylaxis (Product storage error). No additional AE was reported.